What are the indications for minimally invasive targeted interventional therapy for liver cancer? Five indications for minimally invasive targeted interventional technology for liver cancer

In the late stage of cancer interventional treatment, the catheter is sent into the blood vessels supplying the liver cancer under DSA monitoring, chemotherapy drugs are infused through the catheter to kill the liver cancer cells, and then substances that block the blood vessels supplying the liver cancer (embolic agents) are injected through the catheter, causing the liver cancer cells to die of ischemia and hypoxia and starvation.

Liver cancer has an insidious onset and is highly malignant. Most patients are in the middle or advanced stages when they seek medical treatment. The success rate of surgical resection is low, so non-surgical treatment is often used. With the development of minimally invasive interventional radiology, minimally invasive interventional targeted therapy has become the recognized first choice for non-surgical treatment of liver cancer.

Indications for minimally invasive targeted interventional technology:

(1) Preoperative application of this drug before liver tumor resection can shrink the tumor, facilitate resection, and determine the number of lesions and control metastasis.

(2) Advanced liver cancer that cannot be surgically removed, without severe liver and kidney dysfunction, without complete obstruction of the portal vein, and with tumor occupancy rate < 70%;

(3) Small hepatocellular carcinoma;

(4) Patients with surgical failure or recurrence after resection;

(5) Control pain, bleeding and arteriovenous fistula;

(6) Preventive hepatic arterial chemoembolization after hepatocellular carcinoma resection.